Über Dr. Karakas

Derzeitige Tätigkeit und Position

niedergelassener Facharzt

Beruflicher und wissenschaftlicher Werdegang

  • 05.01.1996
    Approbation
  • 01.07.1994
    Eintritt in die Medizinische Klinik III, Universitätsklinikum Frankfurt am Main
  • 31.07.1995
    Dissertation, Magna cum laude
    “Therapie hochmaligner Non-Hodgkin-Lymphome”
  • 01.11.1997
    Eintritt in die Medizinische Klinik III, Universitätsklinikum Ulm
  • 19.07.2001
    Anerkennung „Facharzt für Innere Medizin“
  • 01.06.2001 bis 31.12.2004
    Interims Ärztlicher Direktor des Krankenhauses Bad Orb
  • 03.12.2003
    Anerkennung „Facharzt für Hämatologie und Internistische Onkologie“
  • seit 01.01.2004
    Niederlassung in eigener Praxis

Expertenbeiträge und Publikationen zu speziellen Themen

Randomized study to evaluate the use of high-dose therapy as part of primary treatment for „aggressive“ lymphoma.
Kaiser U, Uebelacker I, Abel U, Birkmann J, Trümper L, Schmalenberg H, Karakas T, Metzner B, Hossfeld DK, Bischoff HG, Franke A, Reiser M, Müller P, Mantovani L, Grundeis M, Rothmann F, von Seydewitz CU, Mesters RM, Steinhauer EU, Krahl D, Schumacher K, Kneba M, Baudis M, Schmitz N, Pfab R, Köppler H, Parwaresch R, Pfreundschuh M, Havemann K.
J Clin Oncol. 2002 Nov 15;20(22):4413-9.

In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia.
Schwänen C, Hecker T, Hübinger G, Wölfle M, Rittgen W, Bergmann L, Karakas T.
Leukemia. 2002 Oct;16(10):2096-105.

Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin’s lymphoma.
Rummel MJ, Chow KU, Karakas T, Jäger E, Mezger J, von Grünhagen U, Schalk KP, Burkhard O, Hansmann ML, Ritzel H, Bergmann L, Hoelzer D, Mitrou PS.
Eur J Cancer. 2002 Sep;38(13):1739-46.

The coexpression of the apoptosis-related genes bcl-2 and wt1 in predicting survival in adult acute myeloid leukemia.
Karakas T, Miething CC, Maurer U, Weidmann E, Ackermann H, Hoelzer D, Bergmann L.
Leukemia. 2002 May;16(5):846-54.

Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study.
Bunjes D, Buchmann I, Duncker C, Seitz U, Kotzerke J, Wiesneth M, Dohr D, Stefanic M, Buck A, Harsdorf SV, Glatting G, Grimminger W, Karakas T, Munzert G, Döhner H, Bergmann L, Reske SN.
Blood. 2001 Aug 1;98(3):565-72.

Interleukin 4 therapy for patients with chronic lymphocytic leukaemia: a phase I/II study.
Lundin J, Kimby E, Bergmann L, Karakas T, Mellstedt H, Osterborg A.
Br J Haematol. 2001 Jan;112(1):155-60.

CD34+ selected cells in mismatched stem cell transplantation: a single centre experience of haploidentical peripheral blood stem cell transplantation.
Bunjes D, Duncker C, Wiesneth M, Stefanic M, Dohr D, Harsdorf S, Karakas T, Reske SN, Bergmann L.
Bone Marrow Transplant. 2000 May;25 Suppl 2:S9-11.

High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia.
Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L.
Ann Oncol. 1998 Feb;9(2):159-65.

Wilms tumor gene (wt1) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34+ progenitors.
Maurer U, Weidmann E, Karakas T, Hoelzer D, Bergmann L.
Blood. 1997 Nov 15;90(10):4230-2. No abstract available.

High levels of Wilms‘ tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome.
Bergmann L, Miething C, Maurer U, Brieger J, Karakas T, Weidmann E, Hoelzer D.
Blood. 1997 Aug 1;90(3):1217-25.

Establishment and characterization of a new, factor-independent acute myeloid leukemia line designated Ei501.
Weidmann E, Brieger J, Karakas T, Maurer U, Pascheberg U, Hoelzer D, Mitrou PS, Bergmann L.
Leukemia. 1997 May;11(5):709-13.

Peripheral T-cell lymphomas respond well to vincristine, adriamycin, cyclophosphamide, prednisone and etoposide (VACPE) and have a similar outcome as high-grade B-cell lymphomas.
Karakas T, Bergmann L, Stutte HJ, Jäger E, Knuth A, Weidmann E, Mitrou PS, Hoelzer D.
Leuk Lymphoma. 1996 Dec;24(1-2):121-9.

Vincristine, doxorubicin, cyclophosphamide, prednisone and etoposide (VACPE) in high-grade non-Hodgkin’s lymphoma–a multicenter phase II study.
Bergmann L, Karakas T, Lautenschlager G, Jager E, Knuth A, Mitrou PS, Hoelzer D.
Ann Oncol. 1995 Dec;6(10):1019-24.

Recombinant human granulocyte-macrophage colony-stimulating factor after combined chemotherapy in high-grade non-Hodgkin’s lymphoma–a randomised pilot study.
Bergmann L, Karakas T, Knuth A, Lautenschläger G, Mitrou PS, Hoelzer D.
Eur J Cancer. 1995 Dec;31A(13-14):2164-8.